Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tumor markers are ‘valuable’ for relapse detection in rare CNS tumors

Key clinical point: Tumor markers can be used to detect relapse in patients with CNS nongerminomatous germ cell tumors.

Major finding: Among evaluable patients, 92% of relapses were detectable by tumor markers.

Study details: A pooled analysis of clinical trial data from 483 patients.

Disclosures: Dr. Fonseca reported having no disclosures, and the researchers disclosed no funding for this study.


Fonseca A et al. ASCO 2020, Abstract 2503.